Thu May 20 2021

Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in patients with moderate and severe COVID-19 pneumonia

The SAVE-MORE study is a multicenter, double-blinded, randomized controlled trial involving 594 hospital patients. It targets those at high risk of severe respiratory failure by measuring elevated suPAR, a plasma biomarker indicating immune activation and previously linked to poor prognosis in various conditions.

The recently published preprint reveals that administering anakinra early, guided by suPAR levels, alongside the existing standard care for hospitalized patients with a bleak prognosis (indicated by a suPAR level above 6 ng/ml), effectively prevented death or severe respiratory failure. Additionally, it increased the number of patients discharged from the hospital without any signs of COVID-19 infection.

Summary of results

  • Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in patients with moderate and severe COVID-19 pneumonia
  • 28-day mortality decreased (Hazard ratio: 0.45; P: 0.045)
  • Anakinra-treated patients were distributed to lower strata of WHO-CPS by day 28 (adjusted odds ratio-OR 0.36; 95%CI 0.26-0.50; P<0.001)
  • Anakinra protected from severe disease or death (6 or more points of WHO-CPS) (OR: 0.46; P: 0.01)
  • Hospital stay was shorter

Conclusion

Starting anakinra treatment early, guided by suPAR, improves the overall clinical status in moderate and severe COVID-19 pneumonia by 2.78 times.

The Hellenic Institute for the Study of Sepsis (HISS) in Greece sponsors the study, with its President and Chairman, Professor Evangelos J. Giamarellos-Bourboulis, leading it. Giamarellos-Bourboulis holds positions as Professor of Internal Medicine and Infectious Diseases at the National and Kapodistrian University of Athens, President of the European Shock Society, and Chairman of the European Sepsis Alliance.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

Quick Triage
TurbiLatex
ELISA
POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates